A new review article published in the World Journal of Pediatrics formalizes the concept of Behçet's spectrum disorders (BSD), providing a genetic framework to help clinicians diagnose and treat children with inflammatory symptoms that resemble Behçet's disease but do not meet classic diagnostic criteria. The framework, introduced in 2020 and now systematically mapped by researchers at Peking Union Medical College Hospital, aims to reduce misdiagnosis and guide appropriate genetic testing and targeted therapies.
Behçet's disease (BD) is a systemic vasculitis characterized by recurrent oral and genital ulcers, but pediatric presentations are often partial or atypical. Additionally, a growing number of monogenic autoinflammatory disorders produce similar mucocutaneous and gastrointestinal symptoms but require different treatments. This diagnostic overlap frequently leads to delayed or incorrect treatment. The BSD framework categorizes these conditions into two tiers: "core BSD" for monogenic diseases that directly affect NF-κB or JAK-STAT signaling pathways—such as HA20, RELA haploinsufficiency, NFKB1 haploinsufficiency, and ELF4 deficiency—and "peripheral BSD" for polygenic or multifactorial entities like recurrent aphthous stomatitis, PFAPA syndrome, DADA2, and trisomy 8-associated disease.
The review, published with the DOI 10.1007/s12519-026-01035-4, highlights NF-κB and JAK-STAT as central inflammatory hubs common across the spectrum. The authors carefully delineate exclusion criteria to distinguish true spectrum members from phenotypic mimics like LIG4 deficiency and IKBKG (NEMO) mutations. This mechanism-oriented approach does not replace existing BD criteria but provides a roadmap for prioritizing genetic testing in early-onset or atypical pediatric cases, potentially shortening diagnostic odysseys.
Clinically, the BSD framework enables earlier recognition of Behçet-like phenotypes and guides the use of targeted therapies such as IL-1, TNF, or JAK inhibitors. It also helps exclude non-spectrum mimics, avoiding unnecessary investigations. "We're not saying these are all the same disease—they're not," the authors stated. "But they converge on the same inflammatory circuits. If a child shows up with recurrent mouth ulcers, fever, and gut inflammation that doesn't quite fit Behçet's criteria, the BSD framework gives us a roadmap for what to test for and why." The framework is especially valuable in early-onset or atypical cases, where genetic testing can distinguish between conditions that look alike but respond to different treatments.
The study was supported by several Chinese research funds, including the National Key R&D Program of China and the CAMS Innovation Fund for Medical Sciences. The World Journal of Pediatrics, which published the review, has an Impact Factor of 7.3. The researchers hope this biology-driven classification will shift pediatric practice from trial-and-error management to precision medicine, offering tangible hope for children with complex, refractory inflammatory conditions.
